Palatin Technologies, Inc.
Save
28.40M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases.

Similar securities

Based on sector and market capitalization

Report issue